A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.

被引：0
|
作者：
Masuishi, Toshiki
Taniguchi, Hiroya
Hamauchi, Satoshi
Komori, Azusa
Kito, Yosuke
Mitani, Seiichiro
Hasegawa, Hiroko
Narita, Yukiya
Kadowaki, Shigenori
Ura, Takashi
Ando, Masashi
Mori, Keita
Tajika, Masahiro
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[4] Shizuoka Canc Ctr Hosp, Clin Res Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Dept Endoscopy, Nagoya, Aichi 464, Japan
[6] Shizuoka Canc Ctr, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
723
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TAS-102 for the treatment of metastatic colorectal cancer
    Salvatore, Lisa
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Loupakis, Fotios
    Falcone, Alfredo
    Masi, Gianluca
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
  • [22] TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
    Zaniboni, Alberto
    Bertocchi, Paola
    Barni, Sandro
    Petrelli, Fausto
    Clinical Colorectal Cancer, 2016, 15 (04) : 292 - 297
  • [23] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
    Ueda, S.
    Tsuboguchi, Y.
    Nakatani, Y.
    Tsuya, A.
    Nishina, S-I.
    Akiyoshi, K.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer
    Huemer, Florian
    Schlintl, Verena
    Hecht, Stefan
    Hackl, Hubert
    Melchardt, Thomas
    Rinnerthaler, Gabriel
    Greil, Richard
    Weiss, Lukas
    CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 159 - +
  • [25] Safety and efficacy on TAS-102 monotherapy in patients with metastatic colorectal cancer according to previous regorafenib
    Kotani, D.
    Shitara, K.
    Fukuoka, S.
    Kuboki, Y.
    Bando, H.
    Okamoto, W.
    Kojima, T.
    Doi, T.
    Ohtsu, A.
    Yoshino, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S364 - S365
  • [26] Colorectal Cancer TAS-102 effective with refractory Recurrence
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144
  • [27] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [28] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [30] TAS-102 followed by regorafenib or the reverse sequence in advanced colorectal cancer
    Nakatani, Y.
    Ueda, S.
    Tsuboguchi, Y.
    Yoshii, Y.
    Akiyoshi, K.
    Tsuya, A.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    ANNALS OF ONCOLOGY, 2018, 29
12345